Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IKS03 |
Synonyms | |
Therapy Description |
IKS03 is an antibody-drug conjugate (ADC) comprising a CD19 antibody linked to a DNA-crosslinking PBD prodrug, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1755). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IKS03 | IKS-03|IKS 03|LCB73|LCB-73|LCB 73 | CD19 Antibody 21 | IKS03 is an antibody-drug conjugate (ADC) comprising a CD19 antibody linked to a DNA-crosslinking PBD prodrug, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1755). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |